The Medicines Company (MDCO)
(Delayed Data from NSDQ)
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Medicines Co. (MDCO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Medicines Co. (MDCO) delivered earnings and revenue surprises of 1.56% and -78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medicines Company's Inclisiran Studies to Continue Unmodified
by Zacks Equity Research
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
Alnylam Reports Positive Data on Lumasiran in Renal Disease
by Zacks Equity Research
Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.
Medicines Company (MDCO) Up 11.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings
by Ekta Bagri
Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.
Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y
by Zacks Equity Research
The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.
The Medicines Company (MDCO) Up 4.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
The Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4
by Zacks Equity Research
Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.
Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y
by Zacks Equity Research
Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.
Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.
What Bargain Hunting? Bet on 6 Stocks With Rising P/E
by Zacks Equity Research
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Is the Options Market Predicting a Spike in Medicines Company (MDCO) Stock?
by Zacks Equity Research
Investors in Medicines Company (MDCO) need to pay close attention to the stock based on moves in the options market lately.
Mallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter
by Zacks Equity Research
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
4 Biotech Stocks to Watch in the New Year
by Zacks Equity Research
We take a look at four companies with a favorable Zacks Rank that performed well in 2017 and are likely to continue on the growth path in 2018 as well.
Can Sucampo Acquisition Turn Mallinckrodt Stock Around?
by Zacks Equity Research
Mallinckrodt (MNK) faced challenging business conditions in 2017 and the company is now looking to revive business with the recently announced Sucampo acquisition.
Is the Options Market Predicting a Spike in The Medicines Company (MDCO) Stock?
by Zacks Equity Research
Surging implied volatility makes The Medicines Company (MDCO) stock lucrative to the option traders.
Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?
by Zacks Equity Research
Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.
Medicines Company to Sell Infectious Disease Unit to Melinta
by Zacks Equity Research
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
by Zacks Equity Research
Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.
Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
by Zacks Equity Research
Mallinckrodt (MNK) sales and earnings declined in the third-quarter due to volume Acthar declines.
Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.
Implied Volatility Surging for The Medicines Company (MDCO) Stock Options
by Zacks Equity Research
The Medicines Company (MDCO) needs investors to pay close attention to the stock based on moves in the options market lately.
Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss
by Zacks Equity Research
The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.